Beyond BRCA: Exploring PARP Combinations in Prostate Cancer

Hear from the experts on how the latest clinical data from ASCO GU 2021 inform leveraging PARP inhibitor&ndash based combinations for treating prostate cancer with and without DNA damage repair alterations. Review their insights in clinical commentaries along with slides a podcast and on-demand Webcast adapted from a live CCO Webinar.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Pfizer TEXT Only